Julia Belluz

speaker

540 appearances 2 recordings 2 series first heard Feb 2026 last heard 8 May

Julia Belluz’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 2 in all, peaking in May 2026 with 1.

Appearances

newest first · ▶ plays the moment

The Ezra Klein Show · GLP-1s and the ‘Wild West’ of Wellness · 8 May 2026 podcast

So hunger has this overlapping pathway with these other motivated behaviors, and it can increase the risk of addictive behavior, it seems.

And so one explanation is that once you've been on these drugs for a while and your appetite starts to normalize, you've lost the weight, and your hunger starts to normalize again, whether the results for addiction are going to actually endure after that.

I think a lot of

People think about these as clear treatments for these addictive behaviors, and that's where I think we don't have the high-quality research we want to have to defend that.

Absolutely and that's where I really feel this like they were just at the beginning of this after we ran this piece where we did the poll and talked about all these other surprising benefits people have experienced.

I got lots of emails about weird like people who were on SSRIs so they were on antidepressants and they start on a GLP-1 and they completely spiral and

And that's not something that I've seen show up in the randomized controlled trials or the research, but it's an experience that people have.

So I think we're going to have lots more of this at the scale that people are taking these drugs.

We're seeing these new drugs are coming down the pipeline.

We're seeing that there's now oral forms of these drugs available.

The drugs are going generic.

We're going to see more and more people on these drugs and learn much more about them.

There's so much we don't know.

Oh, interesting.

This says something about, are you in bodybuilding algorithms?

Oh, interesting.

Okay, that's interesting.

So it's a research compound that's still under study.

It's targeting three hormone receptors.

So semaglutide, ozempic, or regovi is targeting one.

Showing 261–280 of 540 · page 14 of 27